FILING ANALYSIS · MONDAY, OCTOBER 26
CITIUS ONCOLOGY, INC. CTOR — 8-K: Results of Operations and Financial Condition
positive
Citius Oncology reports 120% growth in shipments of LYMPHIR units to U.S. wholesalers during the fiscal fourth quarter, driven by continued institutional demand and expanded commercial team reach, with preliminary unaudited sales of 792 units, a significant increase from the previous quarter.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →